Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

(*) mandatory field


Other search option(s)

Hemolytic anemia due to glucophosphate isomerase deficiency

Synonym(s) -
Prevalence <1 / 1 000 000
Inheritance Autosomal recessive
Age of onset Infancy
  • D55.2
MeSH -
MedDRA -


Glucosephosphate isomerase (GPI) deficiency is an erythroenzymopathy characterized by chronic nonspherocytic hemolytic anemia. Prevalence is unknown but around 50 cases have been reported in the literature so far. GPI deficiency is the second most frequent glycolytic erythroenzymopathy after pyruvate kinase deficiency (see this term). Both males and females can be affected and the hemolytic anemia varies from mild to severe, with episodes of hemolytic crises triggered by viral or bacterial infections. Additional manifestations have been observed in a few patients and include a variable degree of intellectual deficit, hypotonia, muscle weakness, ataxia and dysarthria. Granulocyte disorders and splenomegaly have also been reported. In very rare cases, severe GPI deficiency may be associated with hydrops fetalis and neonatal death. GPI deficiency is inherited as an autosomal recessive trait and is caused by homozygous or compound heterozygous mutations in the GPI gene (19q13.1). To date, around 20 different GPI molecular variants have been identified in affected individuals. GPI is a ubiquitous enzyme that catalyses the conversion glucose-6-phosphate into fructose-6-phosphate, the second step in the glycolytic pathway. Diagnosis is made on the basis of the clinical picture in association with biochemical studies revealing erythrocyte GPI deficiency (between 7 and 60% of normal) and identification of a mutation in the GPI gene by molecular analysis. The differential diagnosis should include other rare causes of chronic hereditary nonspherocytic hemolytic anemia. Molecular prenatal diagnosis is feasible for families of an index case. Blood transfusions may be required for patients with severe anemia. Splenectomy has been shown to be beneficial, particularly during childhood. The prognosis is variable, depending on the severity of the anemia and on the presence of neurological manifestations.

Expert reviewer(s)

  • Pr Pascale DE LONLAY

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.

Captcha image
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.